ARCH Ventures, Newpath Partners and Andreesen Horowitz have teamed up to provide the initial funding for the launch of Orbital Therapeutics, which is developing an RNA platform for the development of new drugs that can be delivered to a wide variety of cell types.
No comments:
Post a Comment